Viagra, sialis, impase -which of them, to whom, when and how?
- Autores: Mazo EВ1, Gamidov SI1, Ovchinnikov RI1
-
Afiliações:
- Edição: Nº 5 (2004)
- Páginas: 42-48
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/275576
- ID: 275576
Citar
Texto integral
Resumo
The study has been performed of the efficacy in the treatment of
erectile dysfunction (ED) of oral drugs affecting nitric oxide: impase
and phosphodiesterase-5 (PDE-5) inhibitors - sildenafil citrate (viagra),
tadalafil (sialis) - alone and in combination with impase. A total
of 218 ED patients aged 21-73 years (mean age 58.1 + 13.2 years) were
divided into 3 groups comparable by the number of the patients, age,
suspected etiology, pathogenesis and ED severity. Group 1 (n = 81)
took viagra in the individually adjusted dose for 6 months; group 2
(n = 64) received sialis in a dose 20 mg for 6 months;
erectile dysfunction (ED) of oral drugs affecting nitric oxide: impase
and phosphodiesterase-5 (PDE-5) inhibitors - sildenafil citrate (viagra),
tadalafil (sialis) - alone and in combination with impase. A total
of 218 ED patients aged 21-73 years (mean age 58.1 + 13.2 years) were
divided into 3 groups comparable by the number of the patients, age,
suspected etiology, pathogenesis and ED severity. Group 1 (n = 81)
took viagra in the individually adjusted dose for 6 months; group 2
(n = 64) received sialis in a dose 20 mg for 6 months;
Bibliografia
- Eardley I. Sethia К., Dean J. Erectile dysfunction: assessment and management in primary care. London: Mosby-Wolfe Publications; 1998.
- Chew K. K., Earle С.M., Stuckey B. G. et al Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int. I. Impot. Res. 2000; 12: 41-45.
- Meulemann E. J., Donkers I. H., Robertson С.et al. Erectile dysfunction: prevalence and effect on the quality of life: Boxmeer study. Ned.Tijdschr. Geneesk. 2001; 145: 576-581.
- Brock G. В., McMahon С.G. Chen К. К. et al. Efficacy and safety of Tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. (Baltimore) 2002; 168: 1332-1336.
- Montorsi F., Salonia A., Montorsi P. et al. May erectile dysfunction predict ischemic heart disease. J. Urol. (Baltimore) 2002; 167 (suppl.): 148 (A591).
- Полетаев А. Б., Морозов С. Г. Естественные аутоантитела и регуляция физиологических функций. В кн.: Полетаев А. Б., Морозов С. Г., Ковалев И. Е. Регуляторная метасистема (иммунонейроэндокринная регуляция гомеостаза). М.: Медицина; 2002. 97-102.
- Мазо Е. Б., Гамидов С. И., Овчинников Р. И. Открытое несравнительное исследование препарата Импазы для лечения эректильной дисфункции. Урология 2003; 3: 28-31.
Arquivos suplementares
